Stada Squeeze-Out Case
If you held Stada shares and tendered in 2017, there is
a very likely possibility of an additional payout.
Please contact us!
Together with our partners, we already represent around 10% of the tender volume, including institutional asset managers.
Background of the Stada Squeeze-Out
Stada Arzneimittel AG, a prominent German pharmaceutical company, was subject to a squeeze-out process initiated by its majority shareholder, Nidda Healthcare GmbH, a consortium of Bain Capital and Cinven. The squeeze-out involved forcing minority shareholders to sell their shares, thereby enabling the majority shareholder to gain complete control of the company.
Legal Framework
The squeeze-out was carried out under German corporate law, which allows a majority shareholder holding at least 95% of the company's shares to compel the remaining shareholders to sell their shares at a fair cash compensation. This legal mechanism is designed to simplify corporate structures and improve operational efficiency but can often lead to disputes over the fairness of the compensation offered to minority shareholders.
AB Litigation's Role
At AB Litigation Partner GmbH, we are representing minority shareholders who contested the squeeze-out. Our primary objective is to ensure that they receive fair compensation for their trade-in shares. We conducted a thorough analysis of Stada's financial health, market position, and prospects to argue for a higher valuation. The Stada squeeze-out case underscored the importance of robust legal representation for minority shareholders in corporate restructuring scenarios.
No financial risk, no allocation of time
While private investors focus on the financial risk, institutional investors focus on the time they have to allocate to an issue. Especially if Stada was a small position in the portfolio, it may not make sense to allocate significant time to it. You don't have to worry about either. We will cover all court and legal costs and keep you up to date.